Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.

Recruiting Phase 1 Interventional Study
Hepatocellular Carcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
30 (estimated)
Sponsor
University Hospital, Lille · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Hepatocellular carcinoma (HCC) is the fifth more common cancer in the world, with high mortality rates, due to the low number of patients who are eligible for therapy with curative intent, like surgical resection. Moreover, surgical resection is associated with a high risk of tumor recurrence, because of the tumor seeding through microscopic intrahepatic vessels that surround the tumor, the so-cal…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Biopsy-proven hepatocellular carcinoma or EASL/AASLD criteria * Single nodule, 3 to 8 cm of largest diameter * Hepatocellular carcinoma eligible for conventional liver resection with curative intent (R0), without preoperative portal vein embolization Exclusion Criteria: * Pe…
Contacts

Emmanuel Boleslawski, MD,PhD

320444260

emmanuel.boleslawski@chru-lille.fr

CONTACT